That is true...and seems that to overcome the final rejection on '465 examiner is asking for data for Kormlyn w food in Cushing's patients, not in healthy subjects that CORT provided.
'368 response should be in next week or so.
Again all ('465 & '368) are belt and suspenders patents that CORT hope to add to Teva litigation. The timeline for resolution remains unchanged even if both applications fail -- mid 2021 IMHO before the earliest date that Teva can launch, which is after the expected Relacorliant Cushing's P3 trial readout.